Imunon Inc. has reported partial results from an ongoing nonhuman primate study designed to examine the immunogenicity of its proprietary Placcine vaccine (PL-COV). The data support Placcine as a viable alternative to mRNA vaccines.
Three months after agreeing to an intellectual property waiver for COVID-19 vaccines, World Trade Organization (WTO) members are discussing expanding it to therapies, diagnostics and devices used in preventing, diagnosing and treating COVID-19 infections.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acasti, Axsome, Genfit, Isoray, Kubota Vision, Merck, Olipass, Teva, Vanda, Versantis, Viatris, Viewpoint.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alligator, Edesa, Eureka, Galecto, IMV, Intercept, Kinarus, Rocket, Tearclear, Trefoil, Zealand.
Maxwell Biosciences Inc. has announced data on the utility of its Claromer drug discovery platform for the treatment and prevention of SARS-CoV-2, and potentially other respiratory viruses, through a series of preclinical in vitro and in vivo studies.
The 2022 Albert Lasker Basic Medical Research Award has been awarded to Richard Hynes, of the Massachusetts Institute of Technology, Erkki Ruoslahti, of the Sanford Burnham Prebys Medical Discovery Institute, and Timothy Springer, of Harvard Medical School “for discoveries concerning the integrins, key mediators of cell-matrix and cell-cell adhesion in physiology and disease.”
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Altimmune, Alumis, CNS, Eisai, Evommune, SAB, Shanghai Henlius, Shionogi, Sparrow.
RSS
